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Abstract
Background: A broad variety of natural environmental stimuli, genotypic influences and timing all contribute to expression
of protective versus maladaptive immune responses and the resulting clinical outcomes in humans. The role of commonly
co-segregating Toll-like receptor 4 (TLR4) non-synonymous single nucleotide polymorphisms Asp299Gly and Thr399Ile in
this process remains highly controversial. Moreover, what differential impact these polymorphisms might have in at risk
populations with respiratory dysfunction, such as current asthma or a history of infantile bronchiolitis, has never been
examined. Here we determine the importance of these polymorphisms in modulating LPS and respiratory syncytial virus
(RSV) - driven cytokine responses. We focus on both healthy children and those with clinically relevant respiratory
dysfunction.
Methodology: To elucidate the impact of TLR4 Asp299Gly and Thr399Ile on cytokine production, we assessed multiple
immune parameters in over 200 pediatric subjects aged 7–9. Genotyping was followed by quantification of pro- and anti-
inflammatory cytokine responses by fresh peripheral blood mononuclear cells upon acute exposure to LPS or RSV.
Principal Findings: In contrast to early reports, neither SNP influenced immune responses evoked by LPS exposure or RSV
infection, as measured by the intermediate phenotype of pro- and anti-inflammatory cytokine responses to these
ubiquitous agents. There is no evidence of altered sensitivity in populations with ‘‘at risk’’ clinical phenotypes.
Conclusions/Significance: Genomic medicine seeks to inform clinical practice. Determination of the TLR4 Asp299Gly/
Thr399Ile haplotype is of no clinical benefit in predicting the nature or intensity of cytokine production in children whether
currently healthy or among specific at-risk groups characterized by prior infantile broncholitis or current asthma.
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Introduction
Genomic medicine seeks to inform clinical practice. It is widely
anticipated that identifying specific components of an individual’s
genome will help determine the optimal approach to health care;
for example, by facilitating the prediction and prevention of
diseases such as asthma [1], or by identifying optimal pharmaco-
logic agents for therapy [2,3]. One early example, the study of
susceptibility to respiratory syncytial virus (RSV), led to much
attention focused on genes that encode proteins of the innate
immune system. Since innate immunity forms the first line of
defense against infection, and its activation shapes the ensuing
protective or maladaptive antigen-specific immune responses that
develop, it is hypothesized that variation in the genes encoding
proteins of the innate immune system will influence human
susceptibility [4–6].
The role of Toll-like receptor 4 (TLR4) polymorphisms in
influencing clinical and immunologic responses to environmental
stimuli is an area of much continuing and conflicting attention.
TLR4 is specifically involved in generating immune responses
against a diverse panel of agonists [7], including controversially,
RSV. Kurt-Jones et al initially reported that TLR4 is key in
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12087initiating innate immune responses of monocytes to the fusion (F)
protein of RSV [8]. These early human data were supported by
experimental animal studies in which RSV was found to persist
longer in the lungs of TLR4-deficient mice compared to TLR4-
expressing controls [9]. At the same time, the validity of these
findings and their broader impact on immune capacity in diverse
human populations has remained controversial, as others, in both
animals and human populations have not replicated these results
[10,11].
The human TLR4 gene harbours two commonly co-segre-
gating single nucleotide polymorphisms (SNP)—Asp299Gly and
Thr399Ile—that alter the amino acid sequence of the TLR4
protein. Experimental systems indicate that the 299Gly SNP is
associated with hyporesponsiveness to TLR4 ligands such as LPS
in vivo and in vitro, and that it acts in a dominant fashion with
respect to the more common Asp299 allele [12,13]. Currently
there is little consensus on how such genetic factors controlling the
innate immune system influence the outcomes of endotoxin
exposure or RSV infection in otherwise healthy children. By way
of example, one study demonstrated that children requiring
admission to hospital for RSV infection carried the TLR4 299Gly
allele at a higher frequency than children with mild disease not
requiring hospitalization [14], however, subsequent independent
work by our group did not identify such a positive association [15],
and another group observed a weak association in the opposite
direction where the more common Asp299 allele was overrepre-
sented in children with severe RSV infection [16]. Most recently,
heterozygosity of Asp299Gly and Thr388Ile was found to be
highly associated with symptomatic RSV disease in high-risk
infants [17]. However, the confounding impact of known clinical
risk factors for severe RSV infection in this cohort, including
prematurity and bronchopulmonary dysplasia, made generaliza-
tion of these data challenging.
LPS and RSV are ubiquitous in the environment. Pediatric
populations may experience substantially higher exposure to both
agents and exhibit a higher burden of disease than adults. Given
the morbidity associated with RSV bronchiolitis and the
observation that RSV infection increases the risk of subsequent
wheezing and asthma, we undertook a rigorous examination of the
functional impact of the TLR4 Asp299Gly and Thr399Ile
polymorphisms on the human immune response to both LPS
exposure and, independently, to RSV infection.
The most significant challenges associated with prior studies of
this question include (i) use of cell lines, reliance on artificial
experimental systems in which cell lines are transfected with TLR4
variants, or use of inbred animal models, the results of which are
often directly extrapolated to highly diverse human populations,
(ii) use of human cells ex vivo as previously frozen samples or
following pre-conditioning regimens with addition of cytokines (ie
IFNc) to culture, both of which have demonstrated potential to
skew the resulting immune responses, (iii) small sample sizes
(frequently less than 100), and (iv) use of different, or undefined,
variants of RSV for re-stimulation. Importantly, the majority of
studies attempt to link SNPs or haplotypes directly to clinical
outcomes, without analysis of the intermediate phenotype of
immune function. Thus, notwithstanding extensive evidence of
the impact of gene by environment by time interactions on a wide
variety of immune and clinical outcomes [18–20], many studies to
date, due to their experimental design, cannot evaluate the impact
of these factors on immune capacity and LPS or RSV specific
responses.
As an alternative approach to better elucidate the immuno-
logical impact of the TLR4 Asp299Gly and Thr399Ile polymor-
phisms on putatively distinct cytokine production in human
populations that interact with a broad diversity of natural
environmental stimuli throughout childhood, we measured
multiple immune parameters in over 200 pediatric subjects aged
7–9 years following acute in vitro re-exposure to LPS or RSV. The
results demonstrate that while some reports link TLR4 As-
p299Gly polymorphism with clinical outcomes of RSV infection,
the haplotype comprised of Asp299Gly and Thr399Ile does not
detectably impact the immune response to RSV, as measured by
the intermediate phenotype of RSV-stimulated cytokine respons-
es nor LPS-driven cytokine production. This conclusion applies
equally to healthy children and those with ‘‘at risk clinical
phenotype’’ characterized by current asthma or a history of
severe bronchiolitis in infancy.
Materials and Methods
Recruitment of child participants and ethics statement
Study approval was obtained from the University of Manitoba
Faculty Committee on Use of Human Subjects in Research.
This 1995 birth cohort (SAGE, Study of Allergy Genes and
Environment) was created from the Manitoba Canada universal
provincial health care registry [20]. Written informed consent was
obtained for 723 children (of whom 207 were randomly selected
for detailed analysis) within a general population survey case-
control cohort. Consented children and parents came to the
Pediatric Allergy Clinic in Winnipeg or mobile Pediatric Allergy
clinic in their community for the detailed assessment used to
characterize the individuals studied in this publication.
In prior studies, 100% of this age group was seropositive for
prior RSV infection, reinforcing the ubiquity of these infections in
the general population. These 7–9 year old children had no
evidence of current upper or lower respiratory tract infection
within one month of recruitment based on histories from child and
parent (no ‘‘colds’’) and no current evidence of a URI on physical
examination.
Clinical assessment of asthma in children
Pediatric allergist assessment was used as the gold standard for
diagnosis of current asthma (ie. within the last 12 months).
Diagnosis was based on history and physical assessment (blinded to
skin prick tests and PC20), according to the Canadian Asthma
Consensus Guidelines [21]. This incorporated a standardized
history and physical sheet, questions regarding cough with/
without colds, wheeze with/without colds, shortness of breath with
activities, colds lasting .2 weeks, response to current medications
and the presence of other allergic conditions, family history of
asthma or personal history of prior/present eczema, hospital,
emergency department and medical visits for breathing difficulty
in the past year, and physical examination for allergic facies, chest
findings and evidence of atopic dermatitis.
Epidemiologic parameters
Bronchiolitis was defined as an ICD-9 (International Classifi-
cation of Diseases) diagnosis of ‘‘acute bronchitis and bronchiol-
itis’’ (466 code) between birth and age 2, which was identified
using the Manitoba Center for Health Policy databases.
PBMC isolation
Blood was collected in tubes containing EDTA, peripheral
blood mononuclear cells (PBMC) were isolated by density
centrifugation, counted (.95% viability by trypan blue exclusion),
and used immediately for short-term primary culture in the
absence of exogenously added cytokines.
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RSV strain Long was cultured on Hep-2 cells at 37uCi nE a g l e ’ s
MEM supplemented with penicillin (100 U/ml), streptomycin
(100 mg/ml), 30 mg/ml L-glutamine (Life Technologies) and 1%
fetal calf sera (Sigma). RSV was titrated by the quantal assay TCID50
performed in 96-well microtiter plates using tenfold dilutions.
Primary cell culture
Freshly isolated PBMC were suspended in complete medium
(RPMI 1640 with 10% heat-inactivated fetal calf serum, 1%
penicillin/streptomycin/fungizone, 0.3 mg/ml L-glutamine and
0.1% 2-mercaptoethanol) with 2.5610
6 cells/ml in 200 mli n9 6w e l l
U bottom plates. Duplicate cultures were stimulated with LPS
(BioXtra, L4391) from Escherichia coli serotype 00011:B4 at 0.05, 0.5
and 5.0 ng/ml from Sigma (St. Louis, MO) or RSV strain Long
(10
4.9 TCID50/ml). LPS purity was validated by i) its inability to
activate other human TLRs expressed in transfected HEK 293 cells,
and ii) the finding that pretreatment with TLR4 blocking antibodies
(10 ug/ml anti-CD284/TLR4, Ebioscience, San Diego, CA), but not
IgG2a isotype control antibodies (Ebioscience), blocks the capacity of
LPS to stimulate cytokine production demonstrate its specificity for
TLR4 (Figure S1). Based on data obtained in preliminary time
course experiments (data not shown), culture supernatants were
h a r v e s t e df o l l o w i n g1o r6d a y sc u l t u r e ,t h er e s p e c t i v et i m eo fp e a k
LPS and RSV driven responses for the cytokines evaluated. The
optimal concentration of LPS stimulation used to evaluate IL-10 and
CCL2 responses was 0.05 ng/ml, with 0.5 ng/ml for IL-1b and
TNFa responses. While the intensity of responses evoked was weaker
in most individuals when sub-optimal concentrations were used, the
conclusions from the data were identical (data not shown).
Human cytokine ELISA
As a safety precaution against infection, culture supernatants
were UV irradiated for one hour to inactivate residual virus prior
to ELISA analysis. Experiments (data not shown) demonstrated
that this had no impact on the sensitivity or precision of the assays
used to evaluate cytokine concentrations. Anti-cytokine capture
and biotinylated detection antibodies were purchased from BD-
Pharmingen (Mississauga, ON, Canada), Endogen (Woburn, MA,
U.S.A.), Biolegend (San Diego, CA, U.S.A.) or R&D Systems
(Minneapolis, MN, U.S.A.) and recombinant cytokine standards
from BD Pharmingen, Endogen or Peprotech (Rocky Hill, NJ,
U.S.A.). They were used as previously described [22,23]. PBMC
supernatants from a minimum of duplicate cultures were assayed.
Each sample was then evaluated in at least two assays, with the
concentration in each calculated from a minimum of three points
falling on the linear portion of titration curves calibrated against
recombinant cytokine standards serially diluted on each plate.
Standard errors typically ranged from 3–10%. All cytokine
standards and antigenic stimuli (LPS and RSV) were each derived
from single lot preparations. Because a large number of different
immune-assays needed to be performed on culture supernatants
derived from the limited pediatric blood volumes drawn, some
samples were consumed before all analyses could be completed.
Thus, some variation exists in the ‘‘n’’ available to assess different
cytokines in both the asthmatic/bronchiolitis groups and control
populations based on availability of materials. No data were
deliberately excluded.
TLR4 Asp299Gly and Thr399Ile Genotyping
The TLR4 allelic variants Asp299Gly (refSNP ID: rs4986790) and
Thr399Ile (refSNP ID: rs4986791) were genotyped by quantitative
PCR assay as previously described [24]. Briefly, genomic DNA was
amplified using a TaqManH Pre-Designed SNP Genotyping Assay
(Asp299Gly #C_11722238_20, Thr399Ile #C_11722237_20, Ap-
plied Biosystems) which contains primers and probes specific for each
allelic variant of the SNP in question. The genotyping assay was
performed using an Applied Biosystems 7300 Real Time PCR System.
Table 1. TLR4 SNP genotypes, allele frequencies and haplotypes.
LR4 SNP frequencies
Asp299Gly Thr399Ile
n % n %
Genotype Genotype
Asp/Asp 183 88.4 Thr/Thr 182 87.9
Asp/Gly 24 11.6 Thr/Ile 25 12.1
Gly/Gly 0 0.0 Ile/Ile 0 0.0
Total 207 100.0 Total 207 100.0
Allele Allele
Asp 390 94.2 Thr 389 94.0
Gly 24 5.8 Ile 25 6.0
Total 414 100.0 Total 414 100.0
TLR4 SNP haplotype frequencies
Asp299Gly Thr399Ile n %
Asp/Asp Thr/Thr 180 87.0
Asp/Asp Thr/Ile 3 1.5
Asp/Gly Thr/Thr 2 0.9
Asp/Gly Thr/Ile 22 10.6
Total 207 100.0
doi:10.1371/journal.pone.0012087.t001
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Associations between Ag-driven responses by subjects were
compared using 2-tailed Mann-Whitney tests (nonparametric
data). All statistics were performed using GraphPad Prism version
3.02 for Windows (GraphPad Software, San Diego, USA).
Results
Asp299Gly and The399Ile TLR4 Genotyping
We genotyped 207 7–9 year old children from the SAGE cohort
(Table 1). TLR4 Asp299Gly and Thr399Ile SNPs were in Hardy-
Weinberg equilibrium, with the common homozygote genotypes
co-segregating in 202 of 207 individuals (97.5%). This cosegrega-
tion is consistent with data demonstrating that these SNPs are
located on the same allele in European populations [25]. Rather
than treating each polymorphism as an independent variable, it is
most helpful to consider the TLR4 haplotypes formed by the
Asp299Gly and Thr399Ile polymorphisms, because different
haplotype structures are observed in different human populations
[26]. Our cohort is essentially comprised of two major haplotypes:
Asp/Asp+Thr/Thr (87.0%) and Asp/Gly+Thr/Ile (10.6%) (See
Table 1). Consequently, to optimize power, all subsequent analysis
was limited to comparing the homozygous (Asp/Asp+Thr/Thr)
and heterozygous (Asp/Gly+Thr/Ile) TLR4 haplotypes.
Common TLR4 haplotypes do not influence LPS-
stimulated cytokine production
The impact of the TLR4 Asp299Gly and Thr399Ile polymor-
phisms on LPS responsiveness remains highly controversial
[12,13,15,26–31]. Many of these studies are quite limited in size.
Given the multiple environmental and genetic factors that
influence and can confound assessment of innate and adaptive
Figure 1. Indistinguishable LPS-driven cytokine responses are evoked in the cells of children with the homozygous (Asp/Asp+Thr/
Thr) vs heterozygous (Asp/Gly+Thr/Ile) TLR4 haplotypes. IL-10 (A), IL-1b (B), TNFa (C) and CCL2 (D) responses were quantified in supernatants
from 1 day primary PBMC cultures, each from an individual child (N). Black bars represent median responses.
doi:10.1371/journal.pone.0012087.g001
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cells directly ex vivo are required. Using acute assays of primary
PBMC cell cultures from 202 healthy children, we found that LPS
stimulated secretion of four characteristic TLR4-driven pro- and
anti-inflammatory cytokines, IL-10, IL-1b, TNFa and CCL2, was
indistinguishable between subjects with the common homozygous
haplotype (Asp/Asp+Thr/Thr) and those with the heterozygous
haplotype (Asp/Gly+Thr/Ile) (Figure 1). With multiple stimula-
tion conditions in culture (ie. different LPS concentrations, virus
stimulation) and subsequent quantification of multiple cytokines in
culture supernatants from these pediatric populations, not all
individuals were assayed for all outcomes. In cases where cell
numbers were limiting, priority was given to RSV stimulation.
The use of ‘maximal’ (5 ng/ml), intermediate (0.5 ng/ml) and
‘low’’ (0.05 ng/ml) LPS concentrations influences the intensity of
cytokine secretion in individuals; however, at none of the other
concentrations studied were differences or trends seen between the
two variants of the TLR4 Asp299Gly polymorphism across this
pediatric population (data not shown).
TLR4 haplotype has no effect on LPS-driven cytokine
responses in pediatric populations stratified by asthmatic
status or prior bronchiolitis
Many functionally important genetic associations are better
revealed in at-risk groups than in general population studies.
Given that some prior studies, often with an n of 20–100,
demonstrated an association between TLR4 polymorphisms and
LPS hyporesponsiveness or clinical outcomes of airway dysfunc-
tion such as asthma and bronchiolitis [14,26,31,32], we conducted
subanalyses of genotype and intermediate phenotype based on
stratification by (i) current asthma (Figure 2) or a prior clinical
history of bronchiolitis in the first two years of life (Figure 3).
Among children carrying the homozygous haplotype (Asp/
Asp+Thr/Thr), asthmatics produce higher levels of IL-10
(p,0.03) in response to stimulation with LPS relative to non-
asthmatics (Figure 2). This supports the body of literature
indicating differences between asthmatics and non-asthmatics in
their innate immune capacity. However, stratification of children
based on current asthma or prior bronchiolitis or the absence of
Figure 2. Similar LPS-driven cytokine responses are expressed by children with differing TLR4 haplotypes, independent of current
asthma. IL-10 (A), IL-1b (B), TNFa (C) and CCL2 (D) were assessed as detailed above. * P,0.05, with all other comparisons P.0.05.
doi:10.1371/journal.pone.0012087.g002
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capacity to express LPS-driven cytokine production between the
two TLR4 haplotypes.
Similar RSV-driven cytokine responses in children with
homozygous or heterozygous TLR4 haplotypes
Results obtained from fresh primary PBMC culture derived
from the 207 children examined in this cohort demonstrate that
the intensity or nature of anti-viral immune responses driven by
RSV infection are not influenced by the TLR4 haplotype
(Figure 4). RSV driven cytokine production is indistinguishable
between these groups, regardless of haplotype.
TLR4 haplotype has no effect on RSV-driven cytokine
responses in children stratified by asthmatic status or
prior bronchiolitis
More targeted analysis, via stratification of children based on
asthma or prior bronchiolitis in infancy, also reveals indistinguish-
able responses in virus-stimulated cytokine production between
individuals with the homozygous TLR4 haplotype (Asp/Asp+Thr/
Thr) or the heterozygous haplotype (Asp/Gly+Thr/Ile) (Figures 5
and 6). These data argue against a functional impact on cytokine
production between these haplotypes. In contrast, the identifica-
tion of differential CCL5 production between asthmatic and non-
asthmatic children in response to RSV stimulation (fure 5D,
p,0.01), underlines the capacity and sensitivity of this method at
distinguishing differences in immune capacity between these
populations [22,23].
Discussion
The role of the haplotype comprised of TLR4 Asp299Gly and
Thr399Ile polymorphisms in shaping immune activation and
subsequent clinical outcomes in humans remains highly contro-
versial. Much of this controversy may stem from the diversity of
experimental systems employed. Here, using freshly derived in vitro
stimulated PBMC in short term culture, we determined whether
Figure 3. Similar LPS-driven cytokine responses exhibited by children with the homozygous (Asp/Asp+Thr/Thr) and heterozygous
(Asp/Gly+Thr/Ile) TLR4 haplotypes with or without prior bronchiolitis. All comparisons yield P.0.05.
doi:10.1371/journal.pone.0012087.g003
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majority of the population, which carries the homozygous
haplotype, in their capacity to mount LPS or RSV-driven immu-
noregulatory cytokine responses. This cohort of .200 individuals
demonstrates that both LPS and RSV-driven responses are
indistinguishable in both groups, regardless of haplotype. Further
stratification of the cohort based on clinical phenotype (current
allergic asthmatic status) also revealed similar LPS- and RSV-
driven responses among individuals of the two genotypes. A third
independent approach, with cohort stratification based on a
history of moderate to severe bronchiolitis/bronchitis during early
infancy, also revealed that indistinguishable cytokine responses
are elicited in these populations. Thus, the TLR4 Asp299Gly +
Thr399Ile heterozygous haplotype has no detectable effect on the
capacity of randomly selected 7–9 year old children to mount
either RSV-stimulated or LPS-driven responses regardless of
whether the children exhibited a clinical phenotype of current
asthma or those with a history of infantile bronchiolitis.
The diversity of findings evident in the literature from
examination of the putative effects of the TLR4 Asp299Gly
polymorphism on LPS responsiveness is likely affected by the
disparity in the cosegregation frequency of the Asp299Gly and
Thr399Ile alleles in various study populations. In the only large
study completed to date other than our own, (n=245 African
subjects) LPS-induced cytokine production by PBMC was not
influenced by TLR4 Asp299Gly genotype [29]. Our data extend
these findings when PBMC (mainly from white children) are
stimulated with LPS at both lower and intermediate concentra-
tions that may reflect environmental conditions better than the
prior widespread use of high concentrations of TLR ligands.
Interestingly, among the 64 statistical comparisons made
between the two haplotypes in this study which showed no
Figure 4. Indistinguishable responses are elicited by respiratory syncytial virus re-exposure in children with differing TLR4
haplotypes. RSV-dependent responses were measured in culture supernatants following six days primary culture. IFNc (A), CXCL10 (B), IL-10 (C) and
CCL5 (D) were measured. All comparisons yield P.0.05.
doi:10.1371/journal.pone.0012087.g004
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cytokines, a single exception was observed — that amongst
children with prior bronchiolitis. Children with prior bronchiolitis
in infancy who were carriers of the common homozygous TLR4
haplotype (Asp/Asp+Thr/Thr) produced marginally higher levels
of IL-10 than did carriers of the heterozygous haplotype (Asp/
Gly+Thr/Ile) if their cells were stimulated at the higher
concentration (0.5 ng/ml) of LPS (p,0.04) (Figure S2). None
of the other cytokines tested in this population differed. While this
borderline statistical significance may be a consequence of multiple
comparisons, it does raise the possibility that under conditions of
increased LPS exposure, TLR4 haplotype may influence LPS-
driven IL-10 production in select children who exhibited severe
pathological symptoms during RSV infection in infancy. Further
experiments specifically addressing this hypothesis, in a larger
cohort specifically constructed for this purpose, would be required
to discriminate between these possibilities.
Despite extensive evidence of the impact of gene by environ-
ment by time interactions on a wide variety of immune and
clinical outcomes, studies to date, due to their experimental design,
were unable to evaluate the impact of the TLR4 Asp299Gly
polymorphism on RSV specific immune responses from individ-
uals with a prior history of bronchiolitis or airway dysfunction.
Here, we used the intermediate phenotype of RSV-specific
cytokine responses to attempt to bridge the gap between genotype
and clinical phenotype. In contrast to the recent study by Tulic et
al., which found associations between RSV-driven cytokine
production and the Asp299Gly (or Thr399Ile) genotype [31], we
i) examined a substantially greater number of individuals (207
versus 24), ii) chose to use fresh PBMC in the absence of pre-
activation with IFNc, iii) stimulated PBMC with a prototypic
strain of RSV and iv) performed subanalysis in clinically different
patient populations. We show that individuals with the Asp/Gly
genotype demonstrate RSV-driven cytokine responses indistin-
guishable from those of individuals carrying the Asp/Asp
genotype. Moreover, while addition of anti-TLR4 to LPS-
stimulated cultures reduced cytokine production to background
levels, inclusion of this blocking antibody had no impact on the
intensity of RSV-stimulated cytokine responses (data not shown).
Collectively, these data strongly argue that neither TLR4 nor these
functional variants directly impact LPS stimulated or RSV-driven
cytokine production in humans. However, it can never be
Figure 5. RSV stimulated cytokine responses in children or without current asthma are not influenced by TLR4 haplotypes. IFNc (A),
CXCL10 (B), IL-10 (C) and CCL5 (D) were measured by ELISA in supernatants from 6 day PBMC cultures. Black bars represent median responses, each
from an individual child (N). ** P,0.01, with all other comparisons P.0.05.
doi:10.1371/journal.pone.0012087.g005
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differences.
In summary, multiple pattern recognition receptors including
various TLR and RLR continue to be linked to resistance to and
resolution of RSV infection in humans and animal models
[32–37]. While some reports have linked TLR4 Asp299Gly
polymorphism with clinical outcomes of RSV infection, our data
show that the haplotype comprised of Asp299Gly and Thr399Ile
does not detectably impact the human immune response to RSV,
as measured by the intermediate phenotype of RSV-stimulated
cytokine responses or that of a well validated TLR4 ligand, LPS.
In this study we did not try to directly link TLR4 SNPs to clinical
outcome, but rather stratified by clinical phenotype (asthma or
bronchiolitis) to see if differences might be enriched in these
groups. Cytokine production from PBMC in a ,200 member
cohort, or in subcohorts characterized by current asthma or a
history of severe bronchiolitis in infancy consistently yield
indistinguishable pro- and anti-inflammatory cytokine production.
As both LPS and RSV can also interact with alternate pattern
recognition receptors [32,38], new possibilities for genomic targets
in the prediction and prevention of harmful diseases such as RSV
infection and asthma await investigation.
Supporting Information
Figure S1 Anti-TLR4 blocking antibodies abrogate LPS-driven
cytokine production. IL-6, IFNc and IL-10 responses in response
to acute activation with 0.5 ng/ml LPS plus/minus blocking
antibodies are shown. Bars represent mean population responses
+/2 SEM.
Found at: doi:10.1371/journal.pone.0012087.s001 (0.29 MB TIF)
Figure S2 LPS-driven IL-10 production is distinct between
children with the homozygous (Asp/Asp+Thr/Thr) and hetero-
zygous (Asp/Gly+Thr/Ile) TLR4 haplotypes in a sub-population
that experienced infantile bronchiolitis. IL-10 responses in
response to acute activation with 0.5 ng/ml LPS are shown with
Figure 6. Prior bronchiolitis/bronchitis does not alter current RSV-driven cytokine responses in cells from children with the
homozygous (Asp/Asp+Thr/Thr) and heterozygous (Asp/Gly+Thr/Ile) TLR4 haplotypes. IFNc (A), CXCL10 (B), IL-10 (C) and CCL5 (D) were
measured by ELISA in supernatants from 6 day PBMC cultures. Black bars represent median responses, each from an individual child (N). All
comparisons yield P.0.05.
doi:10.1371/journal.pone.0012087.g006
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individual children. * P=0.03.
Found at: doi:10.1371/journal.pone.0012087.s002 (0.33 MB TIF)
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